Literature DB >> 11179489

Intravenous readministration of an adenoviral vector performed long after the initial administration failed to induce re-expression of the original transgene in rats.

H Tsujinoue1, S Kuriyama, K Tominaga, H Okuda, T Nakatani, H Yoshiji, T Tsujimoto, T Akahane, K Asada, H Fukui.   

Abstract

Although most humans have been exposed to wild-type adenoviruses in their childhood, titers of neutralizing antibodies against viruses decrease with the passage of time. In the present study, we infused adenoviruses carrying the lacZ gene into the tail vein of rats, and re-infused the same adenoviruses long after the initial administration. However, development of neutralizing antibodies against adenovirus and proliferation of adenovirus-specific T cells were elicited profoundly by adenoviral readministration, and transgene expression was not induced in rats. Our results may have important implications for efficacy considerations when adenoviral vectors are employed in clinical settings for the treatment of cancer.

Entities:  

Mesh:

Year:  2001        PMID: 11179489     DOI: 10.3892/ijo.18.3.575

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  3 in total

Review 1.  Gene therapy for liver regeneration: experimental studies and prospects for clinical trials.

Authors:  Hussein-M Atta
Journal:  World J Gastroenterol       Date:  2010-08-28       Impact factor: 5.742

2.  Repeated adenoviral administration into the biliary tract can induce repeated expression of the original gene construct in rat livers without immunosuppressive strategies.

Authors:  K Tominaga; S Kuriyama; H Yoshiji; A Deguchi; Y Kita; F Funakoshi; T Masaki; K Kurokohchi; N Uchida; T Tsujimoto; H Fukui
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

3.  Stent-based delivery of adeno-associated viral vectors with sustained vascular transduction and iNOS-mediated inhibition of in-stent restenosis.

Authors:  I Fishbein; D T Guerrero; I S Alferiev; J B Foster; N G Minutolo; M Chorny; A M Monteys; K H Driesbaugh; C Nagaswami; R J Levy
Journal:  Gene Ther       Date:  2017-08-23       Impact factor: 5.250

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.